Reports Tuesday, July 28
Report Wednesday, July 29
Report Thursday, July 30
Gilead Sciences (GILD)
Gilead Sciences (GILD) reports its FQ2 ’15 results on Tuesday after the market close. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.78 and a revenue target of $7.570B. Wall Street estimates EPS to come in at $2.64 and revenues to be $7.360B.
The success of Gilead over the past 36 months can be attributed to the company’s strong revenue growth figures which have blown expectations out of the water consistently over the past 2 years. However, this metric has recently experienced a slowdown and is expected to only further decline. As payers begin to balk at the high price tags of Gilead’s Hepatitis C drugs including Sovaldi and Harvoni, sales are expected to be negatively affected.
Despite the potential negatives associated with falling revenue growth, Gilead is in a very strong position in terms of its balance sheet. Gilead has the ability to use its balance sheet to its advantage and potentially acquire desirable businesses in an attempt to bolster growth over the coming years.
Investors will be eager to hear from management with respect to both increasing competition and also their M&A strategy moving forward. Investors have become accustomed to Gilead outperforming analyst expectations, therefore if there is a miss on Tuesday, the stock could potentially experience a significant pull back depending on the severity.
Ford Motor Co (F)
Ford Motor (F) will report its FQ2 ’15 results before the opening bell on Tuesday and both Estimize and Wall Street are predicting an uptick in revenues and EPS QoQ. The struggles have continued YTD for the car manufacturer with the company posting a negative capital return of -7.16%. For FQ2 ’15, the Estimize community predicts an EPS value of $0.36, just one cent above Wall Street’s estimate of $0.35. Dissimilar to EPS, Wall Street actually predict a higher revenue figure of $35.925B compared to Estimize’s forecast of $35.886B.
